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Abstract 
Particulate air pollution is associated with respiratory and cardiovascular morbidity and 
mortality. Recent studies investigated whether and to which extent inhaled ultrafine particles 
are able to translocate into the bloodstream in humans. However, their conclusions were 
conflicting. We developed a physiologically based kinetic model for 99mtechnetium-labelled 
carbon nanoparticles (Technegas®). The model was designed to analyse imaging data. It 
includes different translocation rates and kinetics for free technetium, and small and large 
technetium-labeled particles. It was calibrated with data from an experiment designed to 
assess the fate of nanoparticles in humans after inhalation of Technegas®. The data provided 
time-courses of radioactivity in the liver, stomach, urine and blood. Parameter estimation was 
performed in a Bayesian context with Markov Chain Monte Carlo (MCMC) techniques. Our 
analysis points to a likely translocation of particle-bound technetium from lung to blood, at a 
rate about 2-fold lower than the transfer rate of free technetium. Notably, restricting the model 
so that only free technetium would have been able to reach blood circulation result in much 
poorer fits to the experimental data. The percentage of small particles able to translocate was 
estimated at 12.7% of total particles. The percentage of unbound technetium was estimated at 
6.7% of total technetium. To our knowledge, our model is the first PBPK model able to use 
imaging data to describe the absorption and distribution of nanoparticles. We believe that our 
modeling approach using Bayesian and MCMC techniques provides a reasonable description 
on which to base further model refinement.  
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INTRODUCTION 
Nanoparticles' safety is an integral part of their development process. We regularly witness 
the publication of reports on their toxicity effects in vitro, which beg for the question of their 
significance in vivo (Oberdörster et al., 2005 ; Sayes et al., 2007). A crucial point to answer is 
to what extent and at what rate nanoparticles enter the body and distribute in its various 
tissues. The issue is controversial because nanoparticles are larger than most molecules 
known to penetrate easily in the body, because there are little data on the topic, and because 
the few published results conflict, even for the same type of nanoparticles (Odajima et al., 
2008). Nemmar et al. (2002) and Mills et al. (2006) exposed healthy non-smoking volunteers 
to 99mtechnetium-labelled carbon nanoparticles (Technegas®) in similar conditions. Nemmar 
et al. concluded that nanoparticles translocated from the lung into the blood circulation. Mills 
et al., however, found no evidence to support that claim, reporting that most of their observed 
data were explained by the distribution of free technetium (Tc), unbound to nanoparticles. 
They suggested many explanations for Nemmar et al. (2002) data, such as the need to ccount 
for free technetium kinetics and the fact that in imaging data, several overlapping regions 
contribute to radioactivity in the regions of interest. For instance, the radioactivity measured 
in liver is partially related to technetium concentration in the lung, the skin, the blood and 
adipose tissues. It seems consequently crucial to re-analyse Nemmar et al. data with tools able 
to analyse imaging data and estimate relevant kinetics parameters.  
Therefore, we developed a physiologically based pharmacokinetic (PBPK) model, adapted to 
imaging data analysis, which proposes a realistic, even if simplified, description of the 
mechanisms of absorption, distribution and elimination of technetium-labeled nanoparticles 
and free technetium in the body. In PBPK models, the body is subdivided into various 
compartments representing specific organs linked by blood flows. Compartments are 
characterized by a set of parameters of physiological relevance (e.g., volume and blood 
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perfusion rate) which play a crucial role in explaining the behavior of chemical substances in 
the body, and are invariant across substances. PBPK models offer great flexibility. In 
particular, they are adapted to extrapolations between species, routes or dose levels (Chiu et 
al., 2007). The general PBPK model we proposed was applied to the Nemmar et al. inhalation 
study, with parameters estimation in a Bayesian context. The Bayesian approach is a suitable 
method in the context of mechanistic pharmacokinetic modelling, as they are well suited for 
efficient use of both data and prior knowledge regarding the compound or the physiology of 
the subjects. This permits a reliable parameter estimation for a complex PBPK model such as 
the one used there. 
 
MATERIALS AND METHODS 
Data 
Nemmar et al. collected Technegas® distribution data on 5 healthy male volunteers from 24 to 
47 years old. Technegas® is an aerosol suspension of 99mTc-labelled carbon particles produced 
in high purity argon. The size of individual particles was 5 to 10 nm, confirmed by electron 
microscopy. Volunteers were exposed to approximately 100 MBq of Technegas® in 3 to 5 
breaths. Blood radioactivity data were collected at 1, 5, 10, 20, 30, 45 and 60 minutes after 
Technegas® inhalation, together with gamma-camera images of radioactivity distribution in 
the whole body measured at 5, 10, 20, 30 and 45 minutes. Three regions of interest (liver, 
stomach lumen, bladder content, i.e. urine) were defined on the images. We disposed of their 
intensity apportioned to liver intensity at 5 minutes. We did not use directly intensity 
apportioned to initial lung radioactivity, as shown in Nemmar et al. figure 2, because of the 
very high variability of this measurement among the five subjects.  
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PBPK Model 
The basic model structure is presented in Figure 1, with the whole systems of equations 
detailed in the Appendix. It subdivides the human male body into 24 compartments. This 
number of compartments have been included because imaging data analysis decompose 
imaging regions of interest into many compartments (See next paragraph). However, we used 
a common partition coefficient between organs and blood and the blood fluxes in organs were 
fixed to reference values to avoid overparametrisation of the model. 
As PBPK models deal with organ concentrations, prior to parameters estimation, we had to 
relate the observed data (relative gamma emission intensity or radioactive decay counts) to 
organ concentrations. We defined regions of interest (ROIs) for various organs on a projection 
of a voxel-based anthropomorphic phantom (Zubal et al., 2001). We then counted the voxels 
pertaining to the various tissues and empty space around the body in the volume defined by an 
ROI, and formed the ratios of those counts to the total number of voxel in the volume 
considered. Then, we could relate mathematically ROI intensity and concentrations in organs 
and blood (See Appendix). 
In our model, intake of nanoparticles occurs initially through breathing. Particles are 
deposited in the upper respiratory tract and lungs. Some are rapidly transferred to the 
stomach, due to the swallowing of particles deposited in the mouth (Nemmar et al., 2002). In 
our model, there was consequently a fixed initial condition with a fixed quantity of particles 
and free technetium in the stomach and a fixed one in the lung. As actual exposure dose was 
uncertain, this parameter was among the ones we estimated from the data. Technegas® is not 
homogeneous. Indeed, part of the technetium is unbound and particles have different sizes, 
which can induce different kinetics. We distinguished between three different fractions: 99mTc 
bound to small particles (i.e. able to translocate), 99mTc bound to large particles (i.e. unable to 
translocate) and free 99mTc. The concomitant distribution of 99mTc in these three fractions was 
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modeled. Large particles are assumed to remain at constant concentration in the lung and the 
stomach, as suggested by many publications (Mills et al., 2005; Wiebert et al., 2006). Small 
particles and free 99mTc in the lung can transfer to blood by diffusion. Moreover, free 99mTc 
can translocate from the lung into the gastrointestinal tract as shown by Wiebert et al. (2006). 
This was accounted for in the model, in which we also assumed that this translocation was 
possible for small nanoparticles. Once in the blood, small particles and free 99mTc diffuse to 
the various compartments (except the brain, because Nemmar data show no transfer of 99mTc 
to that organ). Elimination of free 99mTc is supposed to occur by filtration to urine. During the 
time of exposure (60 min), the renal elimination of particle bound-99mTc was neglected, as 
there was only free 99mTc found in urine (Nemmar et al., 2002). To facilitate parameters 
estimation, we assumed that all organs have the same blood over tissue partition coefficient 
value. Some studies have shown that accumulation of 99mTc is similar in most of the organs 
(ICRP, 1999). 
Applying the law of mass conservation for each organ or tissues yields for each model a set of 
differential equations (see Appendix), which were solved by numerical integration using the 
MCSim software version 5.0.0 (Bois and Maszle, 1997) (see 
http://fredomatic.free.fr/page_mcsim.html). The models can be used to simulate the time 
course of radioactivity associated with 99mTc-labeled nanoparticles and free 99mTc in the 
various body compartments, as a function of the quantity of Tc inhaled and of various 
physiological characteristics of the body.  
The PBPK model parameters, and some additional parameters needed to describe the data 
collection process, are described together with the model equations in Supporting 
Information. For physiological parameters (such as organ volumes and blood flows), we used 
the fixed values given in Tables 1 and 2, which are common values for adult males. 
Parameters specific to Technegas® or to the experiments performed were treated as random 
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variables in a Bayesian statistical framework (as detailed below), and their prior sampling 
distributions are given in Table 3. 
 
Statistical analysis 
A statistical measurement error model and a population model were needed to assign values 
for some of the parameters given in Table 3 given their prior distributions and Nemmar et al. 
data. The measurement error model described modeling errors and uncertainties in the data 
collection process (e.g., in the fraction of the particles immediately swallowed, imprecise 
quantity of inhaled Tc, approximate definition of the regions of interest scanned). Inter-
individual variability was quantified in the framework of a population model (Gelman et al., 
1996; Bernillon and Bois, 2000) to try to account for the fact that the five subjects studied 
clearly differed from a kinetic standpoint (see for example in Figure 3 the differences in blood 
radioactivity counts between subjects given the same exposure). 
For a given PBPK model, the measurement errors in blood radioactivity counts were assumed 
to be independent and log-normally distributed, with a geometric mean equal to the PBPK 
model predictions and a geometric standard deviation (GSD) of 1.05 (approximately 5% 
error). The same was assumed for the relative intensities in liver, stomach, and urine, but with 
a GSD of 1.15. Data likelihoods were therefore given by: 
 
( )cXFNY σθ )),,(log(~)log(  (1) 
where the function F(X,θ) corresponds to a PBPK model with input X and parameters θ, and 
σc is equal to either 1.05 or 1.15. 
Pharmacokinetic models and error models were embedded in a hierarchical population 
structure, which considers that each subject's parameter values θ are drawn from a statistical 
distribution G with given population mean µθ and variance σθ. 
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The proposed population model has two major components: the individual and the population 
levels. At the individual level, parameters θ were assumed to be normally or log-normally 
distributed with population means µθ and standard deviations σθ. Truncation bounds of the 
distributions were set on the basis of the limits for plausible values. The hierarchical 
population structure was only applied for the physiological parameters in Table 3 (fractions of 
lungs and volume of urine). The population distributions were normal, with normal 
distribution for population variances with a mean of 1.01 and a standard deviation of 1. In 
contrast, partition coefficients and percentage of free Tc and of small particles were 
considered only as population parameters (i.e., constant across subjects). Two parameters 
were added at individual level, the quantity of inhaled Tc, Qlung(0) and the fraction of the 
inhaled particles immediately swallowed, S_f.  
 
Bayesian Inference via MCMC 
The population model described above was fitted to the observed data with Bayesian 
techniques (Gelman et al., 1995). The Bayesian approach yields a sample of parameter values 
from their joint posterior distribution. From Bayes' theorem, the joint posterior distribution of 
parameters is proportional to the prior distributions of parameters multiplied by the data 
likelihood. The posterior is then an update, using observed data, of what it is known about 
parameters prior to the experiment. 
The first step of the Bayesian approach consists in defining prior distributions that quantify 
the information coming from expertise or from the scientific literature. Prior distributions on 
population parameters and their associated parameters are summarized in Table 3. As little is 
known about nanoparticle kinetics, we generally used very wide uniform distributions to 
define chemical-specific parameters. We had prior information about the first-order transfer 
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rate from lung to blood for free Tc (Klotzerke et al., 1996; Thomeer et al., 2002) so that we 
fixed Kv_lung_1 at 0.04. 
We obtained marginal posterior distributions of the model parameters in Table 3 by randomly 
sampling their values from the joint posterior distributions of all population and individual 
parameters, conditionally on the data from the 5 subjects. For this, we used Markov Chain 
Monte-Carlo simulations (Gilks et al., 1996) (Metropolis-Hastings sampler) performed with 
the MCSim software. After 80000 iterations of 3 parallel Markov chains, their convergence 
was checked by calculating the Gelman and Rubin Rˆ  ratio on the last 20000 iterations 
(Gelman and Rubin, 1992).  
 
RESULTS 
The highest Rˆ  computed for the last 20000 iterations was 1.05, showing that all chains had 
approximately converged. To get a sample from the targeted posterior distribution, we took 
one in 10 vectors among the last 20000 of each chain leading to a posterior sample of 6000 
parameter vectors.  
Figure 2 and 3 provide the data and regression for the relative intensities of stomach and urine 
compared to liver and the radioactivity measured in blood. The fit is globally satisfactory but, 
for each figure, at least one individual dataset is badly fitted. For stomach, subject 5 dataset is 
very different from those of the other individuals. The ratio is almost constant during the first 
four time points and only increases for the last time point. For urine, subject 1 measures are 
underestimated. As for blood concentrations, subject 3 kinetics has not been captured by the 
model. It is however important to note that most of the parameters of the model are common 
to the five individuals, to avoid over-parameterization and difficulties for parameter 
estimation. Individual substantial differences for one parameter could explain the bad fit. For 
instance, subject 1 may have a smaller urine flow rate than the other subjects.  
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We tried an alternative model with no particle (small or large) being able to reach blood 
circulation. This was performed by fixing at 0 the translocation rates for small particles. The 
resulting-Loglikelihood was doubled, and the time-courses of organ intensities and blood 
concentration were not captured by this alternative model, for all the subjects. 
Table 4 gives posterior distribution summaries for the population parameters of the model. It 
appears that only a small proportion of the technetium was free (6.7% of total technetium) but 
also that only a small proportion of the particles were able to reach blood circulation (12.7% 
of total particles). For both parameters, the standard deviation is less than 20% of the mean 
value, which shows that, despite the relative low number of subjects, it was possible to have 
an accurate estimate for these parameters. The translocation rate of particles from lung to 
blood was 2-fold lower than the one of free technetium. Elimination of free technetium was 
rapid and translocation of free technetium from the lung into the stomach was ten times lower 
than its translocation in the blood. Partition coefficients were comparable for particle-bound 
and free technetium. As for individual parameters (data not shown), most of the initial amount 
of particles were in the lung, less than 4% of initially inhaled particles having being 
swallowed. Estimated exposures ranged from 139 to 229 MBq, greater than but consistent 
with the estimate 100 MBq reported by Nemmar et al. (2002). Indeed, there were many 
sources of variation relative to exposure. For instance, the number of breaths varied from 3 to 
5.  
 
DISCUSSION 
The adverse effect of inhaled particles on the cardiovascular system have been 
suggested to result from pulmonary inflammation resulting in systemic consequences and/or 
the direct translocation of particles from the lungs into the systemic circulation (Seaton et al., 
1995; Vermylen et al., 2005). With respect to the possibility that ultrafine particles translocate 
10 
 
from the pulmonary into the blood circulation, various studies have been conducted in 
different animal models. The amount of ultrafine particles that translocated into blood and 
extrapulmonary organs differs amongst these studies (Nemmar et al., 2001; Oberdörster et al., 
2002; Takenaka et al., 2001).  
However, the issue of particle translocation in humans is still contradictory. Brown et 
al. (2002) studied the deposition and clearance for 2 h of an 60 nm technetium-99m–labeled 
aerosol in human volunteers, and found no significant radioactivity over the liver (1.3 ± 
1.2%). This activity was attributed to scatter from the lung and/or overlap of lung parenchyma 
in the liver. Consequently, these authors excluded the occurrence of translocation and, 
although they did not measure radioactivity in blood, they challenged the conclusion of 
Nemmar et al. (2002), that 5-10 nm technetium-labeled particles could pass from the lungs 
into blood and extrapulmonary organs. More recently, Mills et al. (2005) exposed healthy 
non-smoking volunteers to 99mtechnetium-labelled carbon nanoparticles (Technegas®) in 
similar conditions to Nemmar’s study. While the study of Nemmar et al., concluded to a 
translocation of nanoparticles from the lung into the blood circulation, Mills et al., however, 
found no evidence to support the conclusion of Nemmar et al., and have explained the 
findings by the distribution of free technetium (Tc), unbound to nanoparticles. Mills and 
colleagues  investigated this question by using an aerosol of technetium-99m–labeled carbon 
particles (4-20 nm in diameter, but these rapidly formed aggregates of 100 nm in the inhaled 
aerosol). No significant radioactivity was found over the liver. The nature of the radioactivity 
found in blood (4.4 %) consisted mainly of pertechnetate, as analysed by thin layer 
chromatography (TLC). TLC controls of Technegas aerosol collected immediately from the 
generator showed clearly two peaks, one at the origin corresponding to particle-bound 99mTc 
and the other at the solvent front corresponding to oxidized 99mTc, ie, pertechnetate (TcO4-). 
Moreover, when the aerosol was added to whole blood in vitro, two peaks were observed one 
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staying at the application point and the other moving with the solvent front (smaller peak). 
The radioactivity observed after Technegas inhalation consisted mainly in free pertechnetate, 
because additional in vivo oxidation may easily have occurred. No TLC analysis after the 
administration of free pertechnetate in humans or in vivo in animals has been reported by 
these authors.  
These results contrasts with previous findings by Nemmar et al., also based on 
inhaling an aerosol of technetium-99m–labeled carbon particles, where particle-bound 
radioactivity (also assessed by TLC) was detected in blood already after 1 minute, reaching a 
maximum between 10 and 20 minutes, and remaining at this level up to 60 minutes. The TLC 
analysis obtained after adding blood with 99mTc-carbon particles collected from the generator 
showed, at 1 min, only one peak that stayed at the origin. However, at 60 min, in addition to 
the peak at the origin, the presence of a smaller peak of radioactivity at the solvent front has 
been observed (suggestive of in vitro oxidation). Following Technegas inhalation, TLC of all 
blood samples showed, in addition to radioactivity having moved with the solvent front, a 
substantial proportion of radioactivity that stayed at the application point and corresponded to 
particle-bound 99mTc. In contrast, there was only one peak at the solvent front after adding 
99mTc-pertechnetate to blood or in blood collected after the intratracheal administration of 
99mTc-pertechnetate to hamsters. Gamma camera images showed substantial radioactivity over 
the liver and other areas of the body. Consequently, the discrepancies between these two 
studies may be related to the Technegas particles (size and composition) from Technegas 
generators with a different history and age. While further studies with other types of 
radioactive labeling should clarify this issue, the PBPK model developed for 99mtechnetium-
labelled carbon nanoparticles is a useful approach aimed at evaluating the translocation of 
nanoparticles from lungs into the systemic circulation.  
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To our knowledge, our paper presents the first use of PBPK modeling to assess 
distribution of nanoparticles in humans, based on imaging data. It offers a reasonable 
description of Technegas® kinetics in humans, with a relatively low number of parameters (12 
parameters). We showed how information obtained from imaging could be coupled with 
blood concentration measurements to update kinetics parameters distribution in a Bayesian 
framework. We obtained similar results relative to free technetium kinetics than other studies 
(ICRP, 1999; Mills et al., 2005; Wiebert et al., 2006), a high elimination rate through urine, 
and less than 5% of swallowed particles. The estimated fraction of unbound technetium 
(6.7%) was also very coherent with the one found by Mills et al. (2005) at approximately 5%. 
From our study, it appears that passage of particles (of this size and specification) from lung 
into the blood circulation is likely to occur, for a small number of particles, with a rate of 
passage half the known rate for soluble 99mTc. In the paper by Nemmar et al. (2002), there 
was no attempt to quantify the proportion of particles likely to enter the circulation, but 
suggestions of possible high levels. However, we showed here, with the same data, that only a 
small proportion of the particles were able to translocate. Moreover in the paper by Nemmar 
et al. (2002), the rapid and constant liver radioactivity they observed was presented as due to 
particles sequestration in Kupffer cells, with a relatively high level of radioactivity (around 
10%). With our modeling approach, we showed that liver radioactivity was partly explained 
by the presence of lung tissues in the liver imaging region of interest. Moreover, there was no 
need for a specific high partition coefficient to fit the data. Wiebert et al. (2006) performed 
experiments with either stable or unstable labeling. In the first experiment, there was only 
around 0.1 % of initial deposited activity detected in blood as bound to particles after 80 
minutes. This result is close to the Mills study. In contrast, in the experiment with one subject 
exposed to unstable labeling, around 6% of initial deposited activity was found in blood as 
bound to particles. This result is close to our estimate for Nemmar study. This suggests that 
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the percentage of particles able to translocate is very dependent on the experimental design, 
even if high percentages are very unlikely.  
The data used form the experiments described by Nemmar et al. were not specifically 
collected to perform PBPK modeling. We only had data on liver, urine, stomach and blood 
and they only extend to 60 minutes. Moreover, the data reported on the imaging were 
expressed as percentage of initial lung radioactivity which is a relative imprecise measure 
because it is only relative and not quantitative nor specific for chemical identity. The dataset 
contained data of a few organs; a more detailed set, with, in particular lung radioactivity time 
course, would have helped us in the model assessment procedure. We also looked, in the 
literature, for kinetics data on free Tc kinetics, and we could only get prior information about 
the rate of passage from lung into blood. More information on Tc kinetics, in particular on the 
partition coefficient, would permit to refine the assessment of the distribution and kinetics of 
free and bound 99mTc in the model. The expectation is that this would not change our main 
conclusion that the observed translocation cannot be explained solely by the kinetics of free 
technetium.  
To conclude, a model was developed that describes the inhalation and distribution of 
Techngas in humans as representative of carbon nanoparticles. Although lacking measured 
tissue-to-blood partition coefficients and independent verification to a secondary data, the 
modeling approach using Bayesian and MCMC techniques provides a reasonable description 
on which to base further model refinement.  
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APPENDIX : PBPK model equations 
The following equations are for the quantities Q of 99mTc-labeled nanoparticles and free 99mTc 
in each compartment. Quantities were expressed in MBq, which is the unit of radioactivity 
used in Nemmar et al. paper. Concentrations C, in MBq/L, were obtained at any time by 
dividing Q by the compartment volume. Volumes were in L, time in min, flows and rates in 
L/min. Q and C depended on time but we omit the time argument when possible for lighter 
notation. A list of parameters and their values can be found in Tables 1-3 of the main text. 
For adipose tissue, adrenals, bone marrow, brain, breast, heart, kidneys, muscles, other organs 
and tissues, pancreas, skin, spleen, testes and thyroid: 
 

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i
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i
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CCF
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Q
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where Fi are defined in Table 2, and Pi are tissue over blood partition coefficients (Table 3). 
For the lung: 
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where Kv_lung and Km_lung are respectively the direct transfer rate from lung to blood and the 
translocation rate from lung to stomach lumen (in L/min). Initial dose in the lung, Qlung(0) is 
one of the parameters and is estimated from the data for each of the subjects. 
For the liver, blood feeds from the arterial pool, spleen, pancreas, stomach and gut: 
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Total blood flow to the liver, Fliver, is the sum of extra-portal flow and incoming flows from 
spleen, pancreas, gut and stomach: 
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 stomachgutpancreasspleeneportliver FFFFFF ++++=  (4) 
For urine: 
 vene_renal
urine CK
t
Q
×=
∂
∂
 (5) 
where Ke_renal is the urinary clearance rate (in L/min). 
For arterial blood: 
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For venous blood: 
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where i designate the following organs or tissues: adipose tissue, adrenals, bone marrow, 
brain, breast, heart, kidneys, liver, muscles, other organs and tissues, skin, testes and thyroid  
The gastro-intestinal tract is described by four compartments: 
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where Fstom_lumen is the transport rate from the stomach lumen to the gut lumen (L/min). These 
transport rates were assumed to negligible during the experiment.  
As part of the inhaled particles have been swallowed, we introduced a parameter (S_f) so that 
Qstom_lumen(0)= S_f.Qlung(0). This parameter is estimated for all subjects. 
We had first to relate the observed data (relative gamma emission intensity or radioactive decay 
counts) to the above quantities or concentrations. We defined regions of interest (ROIs) for various 
organs on a projection of a voxel-based anthropomorphic phantom (The Zubal Phantom - Voxel-
Based Anthropomorphic Phantoms – [http://noodle.med.yale.edu/zubal/index.htm]). We then 
counted the voxels pertaining to the various tissues and empty space around the body in the volume 
defined by an ROI, and formed the ratios of those counts to the total number of voxel in the volume 
considered.  
The following table gives the fractions estimated (they do not add up to 1 since minor tissues 
and empty space are excluded): 
Tissue Region Of Interest 
  "Lung" "Liver" "Stomach 
lumen" 
"Bladder" 
 
     
Adipose  0.05 0.05 0.09 0.14 
Liver  - 0.39 -  
Lung  0.44 (estimated) (estimated) - 
Muscle  0.1 0.1 0.13 0.08 
Skin  0.02 0.02 0.02 0.02 
Spleen  - - 0.1 - 
Stomach lumen  - - 0.23 - 
Urine  - - - 0.17 
 
We account for the blood present in the organs, which contributes to the intensity of 
radioactivity of the studied organs. The blood volume per organ was obtained from Leggett 
and Williams (1995) who provide blood content in percentage of total blood volume for a 
reference middle-aged man. In the equations for intensity, we added the blood contribution 
when it could be substantial, i.e. in liver (31%), lung (140%), spleen (52%). 
The intensities at time t in liver, stomach lumen and urine were computed similarly: 
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where Kintensity is a proportionality constant, Kd is the decay rate constant for 99mTc (0.001922 
min-1, ), and f(i,j) the fraction of tissue i present in a ROI labeled j.  
Vurine(t) is the volume of urine (in L) at time t, computed as: 
 
tFVtV urineurineurine ×+= )0()(  (15) 
where Vurine(0) is the volume of urine (in L) in the bladder at the start of exposure and Furine is 
the urinary flow rate (L/min). 
 
The recorded radioactivity counts in blood (in CPM/g of blood) where obtained from Cven (in 
MBq/L) by: 
 
( )tKtCtC dvenvenr ⋅−××= exp)(60000)(_  (16) 
The number 60000 comes from the conversion from MBq/L in CPM/g. 
We described jointly the kinetics of small particles-bound-99mTc and free 99mTc. We 
introduced the fraction of 99mTc bound, Bound, and the fraction of small particles, Small, as 
model parameters and defined two set of variables (the concentrations related to large 
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particles-bound-99mTc are constant over time, so that there is no use to define a set of 
variables for them). Variables Qi_0 corresponded to 99mTc bound to small particles (i.e., 
labeled nanoparticles) in each compartment, with Qi_1 corresponding to free 99mTc.  Similarly, 
we defined concentration sets Ci_0 and Ci_1 in MBq/L. 
The inhaled small particles-bound-99mTc and unbound-99mTc concentrations were functions of 
the total concentration inhaled Cinh: 
 inh0inh CSmallBoundC ××=_  (17) 
 inh1inh CBoundC ×−= )1(_  (18) 
Equations 1 to 3, and 5 to 11 were duplicated (one set for bound 99mTc, the other for free 
99mTc). Output equations 12 to 14 and 16 did not change, and the concentrations Cadip, Clung, 
Cliver, etc. of total 99mTc which they use were at each time computed as the sum of the bound 
(to small and large particles) and free concentrations. 
 
TABLE 1  
Organ or tissue volumes calculated for a standard man of 1.76 m and 73 kg, using the organ 
weights given by the ICRP 2002 Pub 89 (Table 2.8 p.18; Table 2.9 p.19). Density for the 
organs is supposed equal to 1 excepted for adipose tissues (density 0.9) and bones (density 2) 
Tissue or organ Symbol Value (L) 
Adipose Vadip  18.8 
Adrenals Vadrenal  0.014 
Arterial blood Vart 1.40 
Venous blood  Vven  4.20 
Bone  Vbone  2.75 
Brain  Vbrain  1.45 
Breast  Vbreast  0.025 
Gut  Vgut  1.02 
Gut lumen Vgut_lumen 0.65 
Heart  Vheart  0.33 
Kidney  Vkidney  0.31 
Liver  Vliver  1.80 
Lung  Vlung  0.50 
Bone marrow  Vmarrow 3.65 
Muscles Vmuscle  29.0 
Others Vother  7.06 
Pancreas  Vpancreas  0.14 
Skin  Vskin  3.30 
Spleen  Vspleen  0.15 
Stomach  Vstomach  0.15 
Stomach lumen Vstom_lumen 0.25 
Testes Vtestes 0.056 
Thyroid Vthyroid 0.019 
 
TABLE 2                                                                                                                      
Urine flow rate and blood flows for the various organs or tissues. These have been computed 
using cardiac output, percent blood flows per tissue mass and organ weights given in ICRP 
2002 Pub 89 (Table 2.8  p18-19, Table 2.39 p28, Table 2.40  p29) or provided by William & 
Leggett (1989). 
Tissue or organ Symbol Value (L/min) 
Adipose Fadip 0.564 
Adrenals Fadrenal 0.02 
Brain  Fbrain  0.78 
Breast  Fbreast  0.00 
Gut  Fgut 0.98 
Heart  Fheart  0.35 
Kidney  Fkidney  1.23 
Liver  Feport 0.45 
Lung  Ftotal 6.72 
Bone marrow  Fmarrow  0.29 
Muscles Fmuscle  1.11 
Others Fother 0.19 
Pancreas  Fpancreas 0.065 
Skin  Fskin 0.33 
Spleen  Fspleen  0.19 
Stomach  Fstomach 0.065 
Testes Ftestes 0.004 
Thyroid Fthyroid 0.094 
Urine flow rate Furine 0.001 
 
 
TABLE 3                                                                                                                             
MCMC-sampled physiological or experiment-specific parameters. Population distributions. 
references ICRP 2002 Pub 89, p.99. 
Parameter Symbol Distribution Unit 
Quantity of inhaled 
Technetium 
Qlung(0) Uniform (0, 300) MBq 
Fraction of the inhaled particles 
immediately swallowed 
S_f Uniform (0, 0.2) - 
Volume of urine in bladder at 
start of exposure 
Vurine(0) Uniform (0, 0.5)i L 
Fraction of lung in liver 
imaging region 
f(lung, liver) Normal [0.02, 0.01] (0, 1)ii – 
Fraction of lung in stomach 
imaging region  
f(lung, stom) Normal [0.02, 0.01] (0, 1) – 
Fraction of small 
nanoparticles 
Small Uniform (0,1) – 
Fraction of Technetium bound 
to nanoparticles 
Bound Uniform (0,1) – 
Partition coefficient for free 
Technetium 
P1 Uniform (0, 20) – 
Partition coefficient for small 
particles 
P0 Uniform (0, 20) – 
Translocation rate from lung 
to blood for free Technetium 
Kv_lung1 0.04 L/min 
Translocation rate from lung 
to blood for small particles 
Kv_lung0 Uniform (0, 0.1) L/min 
Translocation rate from lung 
to stomach lumen  
Km_lung Uniform (0, 0.1) L/min 
Free Technetium renal 
elimination rate 
Ke_renal1  Uniform (0, 1) L/min 
Small particles renal 
elimination rate 
Ke_renal0  0 L/min 
 
                                                 
i
  Between brackets are the boundaries of the distribution 
ii
 Between square braces are the mean and standard deviation of the distribution. 
TABLE 4  
Model posterior parameter estimates. 
Parameter Arithmetic mean and 
standard deviation 
Small 0.127 ± 0.0113 
Bound 0.93 ± 0.0158 
f(lung,liver) 0.0129 ± 0.00437  
f(lung,stom) 0.00564 ± 0.00327  
Kv_lung_0 (L/min) 0.0165 ± 0.000952 
P
_0 0.445 ± 0.0295 
Vu_zero (L) 0.0196 ± 0.00779  
Km_lung (L/min) 0.0049 ± 0.000868 
Ke_renal_1 (L/min) 0.798 ± 0.134  
P
_1 0.499 ± 0.164 
 
TABLE 5  
Model posterior parameter estimates. 
Parameter Mean and standard 
deviation 
Small 0.127 ± 0.0113 
Bound 0.93± 0.0158 
f(lung,liver) 0.0129 ± 0.00437  
f(lung,stom) 0.00564 ± 0.00327  
Kv_lung_0 (L/min) 0.0165 ± 0.000952 
P
_0 0.445 ± 0.0295 
Vu_zero (L) 0.0196 ± 0.00779  
Km_lung (L/min) 0.0049 ± 0.000868 
Ke_renal_1 (L/min) 0.798 ± 0.134  
P
_1 0.499 ± 0.164 
 
FIG. 1. Schematic representation of the common basis for the physiologically based 
pharmacokinetic models we used for a human male. The body is subdivided into 
compartments describing organs or diffuse tissues. Nanoparticles or free technetium are 
transported or transferred through the compartments. 
FIG. 2. Time course of radioactivity of stomach lumen and urine for five human subjects, 
based on Nemmar et al. data. We present model predicted data (lines) and actual data. 
Radioactivity is expressed as ratio of liver radioactivity. Black circles : Subject 1; white 
circles : subject 2; crosses : subject 3; plusses : subject 4; squares : subject 5.  
FIG. 3. Time course of radioactivity of blood for five human subjects, based on Nemmar 
et al. data. We present model predicted data (lines) and actual data. Black circles : Subject 
1; white circles : subject 2; crosses : subject 3; plusses : subject 4; squares : subject 5. 
 
LUNGS
AIRWAYS
STOMACH
BRAIN
HEART
FAT
MARROW
MUSCLES
SURRENALS
SKIN
THYROID
BREAST
KIDNEYS
OTHERS
URINE
PANCREAS
SPLEEN
STOMACH LUMEN
GUT
TESTES
LIVER
GUT LUMEN
V
E
N
O
U
S
B
L
O
O
D
A
R
T
E
R
I
A
L
B
L
O
O
D
 
 
Figure 1. 
 
 Figure 2. 
10 20 30 40 50
0
1
2
3
4
5
6
Time (min)
Urine
1
2
3
4
5
6
Stomach
104
105
10 20 30 40 50 60 70
R
a
di
o
ac
tiv
ity
 
(C
PM
/g
 
o
f b
lo
o
d)
Time (min)
 
 
 
 
 
 
 
 
FIG. 3. 
